High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors

I. Majolino, P. Corradini, R. Scimè, M. Falda, A. Bosi, C. Tarella, M. Musso, A. Olivieri, M. Boccadoro, R. Marcenò, A. Santoro, A. Pileri

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A total of 30 multiple myeloma patients (M = 23, F = 7; age 31-55 years, median 48) were allografted with peripheral blood stem cells (PBSC) from HLA-identical siblings. Time to transplantation was 3-107 months (median 8). Prior chemotherapy lines varied from 1 to 6 (median 1). Four patients were in complete remission (CR), 11 in partial remission (PR), 13 were considered to be nonresponders, and two had progressive disease. Most were conditioned with busulfan-melphalan. PBSC were collected by apheresis after G-CSF or sequential GM-CSF and G-CSF. The patients were grafted with 4.4-24.1 × 106/kg CD34+ (median 7.9) and 0.9-7.9 × 108/kg CD3+ cells (median 2.3). GVHD prophylaxis was methotrexate-cyclosporine. Engraftment was complete and rapid. Grades II-IV acute GVHD (aGVHD) developed in 16 (53% , but was grade III-IV only in five (17%); chronic GVHD (cGVHD) developed in 17 out of the 24 evaluable patients (71%). A total of 18 patients (71%) attained CR after transplantation. TRM was 30% overall, 16% at 100 days. There was only one relapse. Overall survival and event-free survival at 73 months were 60% and 67%, respectively. PCR negativity for IgH-gene rearrangement occurred in all persistently CR patients studied. PBSC allograft can induce long remissions, because of profound suppression of the neoplastic clone that is probably linked to the antitumor effect of cGVHD.

Original languageEnglish
Pages (from-to)767-773
Number of pages7
JournalBone Marrow Transplantation
Volume31
Issue number9
DOIs
Publication statusPublished - May 2003

Fingerprint

Multiple Myeloma
Siblings
Tissue Donors
Recurrence
Granulocyte Colony-Stimulating Factor
Transplantation
Busulfan
Blood Component Removal
Melphalan
Gene Rearrangement
Granulocyte-Macrophage Colony-Stimulating Factor
Methotrexate
Cyclosporine
Disease-Free Survival
Allografts
Peripheral Blood Stem Cells
Clone Cells
Drug Therapy
Polymerase Chain Reaction
Survival

Keywords

  • Allogeneic
  • GVHD
  • Myeloma
  • PBSC
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. / Majolino, I.; Corradini, P.; Scimè, R.; Falda, M.; Bosi, A.; Tarella, C.; Musso, M.; Olivieri, A.; Boccadoro, M.; Marcenò, R.; Santoro, A.; Pileri, A.

In: Bone Marrow Transplantation, Vol. 31, No. 9, 05.2003, p. 767-773.

Research output: Contribution to journalArticle

Majolino, I, Corradini, P, Scimè, R, Falda, M, Bosi, A, Tarella, C, Musso, M, Olivieri, A, Boccadoro, M, Marcenò, R, Santoro, A & Pileri, A 2003, 'High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors', Bone Marrow Transplantation, vol. 31, no. 9, pp. 767-773. https://doi.org/10.1038/sj.bmt.1703924
Majolino, I. ; Corradini, P. ; Scimè, R. ; Falda, M. ; Bosi, A. ; Tarella, C. ; Musso, M. ; Olivieri, A. ; Boccadoro, M. ; Marcenò, R. ; Santoro, A. ; Pileri, A. / High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. In: Bone Marrow Transplantation. 2003 ; Vol. 31, No. 9. pp. 767-773.
@article{59c95eae66ed4b9ca28d519d670df96b,
title = "High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors",
abstract = "A total of 30 multiple myeloma patients (M = 23, F = 7; age 31-55 years, median 48) were allografted with peripheral blood stem cells (PBSC) from HLA-identical siblings. Time to transplantation was 3-107 months (median 8). Prior chemotherapy lines varied from 1 to 6 (median 1). Four patients were in complete remission (CR), 11 in partial remission (PR), 13 were considered to be nonresponders, and two had progressive disease. Most were conditioned with busulfan-melphalan. PBSC were collected by apheresis after G-CSF or sequential GM-CSF and G-CSF. The patients were grafted with 4.4-24.1 × 106/kg CD34+ (median 7.9) and 0.9-7.9 × 108/kg CD3+ cells (median 2.3). GVHD prophylaxis was methotrexate-cyclosporine. Engraftment was complete and rapid. Grades II-IV acute GVHD (aGVHD) developed in 16 (53{\%} , but was grade III-IV only in five (17{\%}); chronic GVHD (cGVHD) developed in 17 out of the 24 evaluable patients (71{\%}). A total of 18 patients (71{\%}) attained CR after transplantation. TRM was 30{\%} overall, 16{\%} at 100 days. There was only one relapse. Overall survival and event-free survival at 73 months were 60{\%} and 67{\%}, respectively. PCR negativity for IgH-gene rearrangement occurred in all persistently CR patients studied. PBSC allograft can induce long remissions, because of profound suppression of the neoplastic clone that is probably linked to the antitumor effect of cGVHD.",
keywords = "Allogeneic, GVHD, Myeloma, PBSC, Transplantation",
author = "I. Majolino and P. Corradini and R. Scim{\`e} and M. Falda and A. Bosi and C. Tarella and M. Musso and A. Olivieri and M. Boccadoro and R. Marcen{\`o} and A. Santoro and A. Pileri",
year = "2003",
month = "5",
doi = "10.1038/sj.bmt.1703924",
language = "English",
volume = "31",
pages = "767--773",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors

AU - Majolino, I.

AU - Corradini, P.

AU - Scimè, R.

AU - Falda, M.

AU - Bosi, A.

AU - Tarella, C.

AU - Musso, M.

AU - Olivieri, A.

AU - Boccadoro, M.

AU - Marcenò, R.

AU - Santoro, A.

AU - Pileri, A.

PY - 2003/5

Y1 - 2003/5

N2 - A total of 30 multiple myeloma patients (M = 23, F = 7; age 31-55 years, median 48) were allografted with peripheral blood stem cells (PBSC) from HLA-identical siblings. Time to transplantation was 3-107 months (median 8). Prior chemotherapy lines varied from 1 to 6 (median 1). Four patients were in complete remission (CR), 11 in partial remission (PR), 13 were considered to be nonresponders, and two had progressive disease. Most were conditioned with busulfan-melphalan. PBSC were collected by apheresis after G-CSF or sequential GM-CSF and G-CSF. The patients were grafted with 4.4-24.1 × 106/kg CD34+ (median 7.9) and 0.9-7.9 × 108/kg CD3+ cells (median 2.3). GVHD prophylaxis was methotrexate-cyclosporine. Engraftment was complete and rapid. Grades II-IV acute GVHD (aGVHD) developed in 16 (53% , but was grade III-IV only in five (17%); chronic GVHD (cGVHD) developed in 17 out of the 24 evaluable patients (71%). A total of 18 patients (71%) attained CR after transplantation. TRM was 30% overall, 16% at 100 days. There was only one relapse. Overall survival and event-free survival at 73 months were 60% and 67%, respectively. PCR negativity for IgH-gene rearrangement occurred in all persistently CR patients studied. PBSC allograft can induce long remissions, because of profound suppression of the neoplastic clone that is probably linked to the antitumor effect of cGVHD.

AB - A total of 30 multiple myeloma patients (M = 23, F = 7; age 31-55 years, median 48) were allografted with peripheral blood stem cells (PBSC) from HLA-identical siblings. Time to transplantation was 3-107 months (median 8). Prior chemotherapy lines varied from 1 to 6 (median 1). Four patients were in complete remission (CR), 11 in partial remission (PR), 13 were considered to be nonresponders, and two had progressive disease. Most were conditioned with busulfan-melphalan. PBSC were collected by apheresis after G-CSF or sequential GM-CSF and G-CSF. The patients were grafted with 4.4-24.1 × 106/kg CD34+ (median 7.9) and 0.9-7.9 × 108/kg CD3+ cells (median 2.3). GVHD prophylaxis was methotrexate-cyclosporine. Engraftment was complete and rapid. Grades II-IV acute GVHD (aGVHD) developed in 16 (53% , but was grade III-IV only in five (17%); chronic GVHD (cGVHD) developed in 17 out of the 24 evaluable patients (71%). A total of 18 patients (71%) attained CR after transplantation. TRM was 30% overall, 16% at 100 days. There was only one relapse. Overall survival and event-free survival at 73 months were 60% and 67%, respectively. PCR negativity for IgH-gene rearrangement occurred in all persistently CR patients studied. PBSC allograft can induce long remissions, because of profound suppression of the neoplastic clone that is probably linked to the antitumor effect of cGVHD.

KW - Allogeneic

KW - GVHD

KW - Myeloma

KW - PBSC

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=10744220917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744220917&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703924

DO - 10.1038/sj.bmt.1703924

M3 - Article

C2 - 12732883

AN - SCOPUS:10744220917

VL - 31

SP - 767

EP - 773

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -